Hydroxychloroquine for Cardiac and General Surgery Patients

Phase-Based Progress Estimates

Effectiveness

Safety

Duke Health, Durham, NCCardiac and General Surgery PatientsHydroxychloroquine - Drug

You have a chance of qualifying for this trial. We made sure your application will take less than 5 minutes.

Eligibility

18+

All Sexes

What conditions do you have?

Select

Eligibility

18+

All Sexes

What conditions do you have?

Select

Study Summary

This trial will see if hydroxychloroquine can help reduce brain swelling after surgery.

Treatment Effectiveness

Effectiveness Progress

3 of 3

This is further along than 93% of similar trials

Hydroxychloroquine

Hydroxychloroquine sulfate

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Postoperative day 1-5

Postoperative day 1-5

Ratio of T1 relaxivity difference

Trial Safety

Safety Progress

3 of 3

This is further along than 85% of similar trials

Hydroxychloroquine

Hydroxychloroquine sulfate

Side Effects for

Sarilumab 150 mg by PFS (Extension Phase)

13%Upper respiratory tract infection

6%Neutropenia

6%Sinusitis

5%Alanine aminotransferase increased

5%Urinary tract infection

4%Injection site erythema

4%Accidental overdose

4%Bronchitis

3%Injection site pruritus

2%Nasopharyngitis

2%Thrombocytopenia

2%Contusion

1%Small intestinal obstruction

1%Lumbar spinal stenosis

1%Vertebrobasilar insufficiency

1%Thrombophlebitis superficial

1%Chronic obstructive pulmonary disease

1%Arthralgia

1%Traumatic arthritis

1%Nephrolithiasis

1%Hypertension

1%Transient ischaemic attack

1%Vomiting

1%Endometrial hyperplasia

1%Cataract

1%Pneumonia

1%Anaemia

1%Pancreatic carcinoma metastatic

1%Wolff-Parkinson-White syndrome

1%Coronary artery occlusion

1%Osteoarthritis

1%Rheumatoid lung

1%Pharyngitis

1%Femoral neck fracture

1%Leukopenia

This histogram enumerates side effects from a completed 2016 Phase 3 trial (NCT02057250) in the Sarilumab 150 mg by PFS (Extension Phase) ARM group. Side effects include: Upper respiratory tract infection with 13%, Neutropenia with 6%, Sinusitis with 6%, Alanine aminotransferase increased with 5%, Urinary tract infection with 5%.

Trial Design

5 Treatment Groups

Phase 3

1 of 5

Phase 1

1 of 5

Phase 4

1 of 5

Phase 2

1 of 5

Phase 5

1 of 5

Experimental Treatment

30 Total Participants · 5 Treatment Groups

Primary Treatment: Hydroxychloroquine · No Placebo Group · Phase 4

Phase 3

Drug